Table 1 Baseline characteristics (per protocol data set, n = 202) of patients randomized to one of three patient groups after end of run-in-period

Baseline characteristicPlacebo, n = 6350 mg Petadolex, n = 7175 mg Petadolex, n = 68Global difference between groups, p
Values are medians (5th and 95th percentiles) and are rounded. Significance testing for continuous data: rank analysis of variance for frequencies: χ2 test, exact if necessary.
Age, y42 (22–58)41 (22–60)42 (22–60)0.80
Height, cm168 (158–189)167 (158–181)169 (157–185)0.41
Weight, kg69 (53–98)66 (52–98)66 (50–100)0.38
Gender, % F7987790.37
Type of migraine, %
    With aura19 (n = 12)23 (n = 16)28 (n = 19)0.16
    Without aura76 (n = 48)77 (n = 55)72 (n = 49)
    Both5 (n = 3)0 (n = 0)0 (n = 0)
Attack frequency3 (2–7)3 (2–6)3 (2–7)0.17
Attack days/mo3 (2–8)3 (2–7)3 (2–7)0.17
Attack duration, h11 (2–46)13 (4–61)12 (4–45)0.81
Attack intensity score2 (1.7–2.7)2 (1.5–3)2 (1.5–3)0.32